HC Wainwright Reaffirms “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $5.75 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 56.25% from the company’s current price.

Separately, BTIG Research assumed coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price for the company.

VYNE Therapeutics Price Performance

Shares of VYNE stock traded up $0.22 during trading hours on Monday, hitting $3.68. The stock had a trading volume of 108,679 shares, compared to its average volume of 90,237. The firm has a market capitalization of $54.28 million, a PE ratio of -4.28 and a beta of 1.30. The stock’s 50 day moving average is $2.87 and its 200 day moving average is $2.26. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $3.84.

Hedge Funds Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.